Dry-Clox®
(cloxacillin benzathine)
Treat dry cow mastitis with an antibiotic that fights Gram-positive bacteria
(cloxacillin benzathine)
Details
Dry-Clox® (cloxacillin benzathine) is a dry cow antibiotic mastitis treatment that provides bactericidal activity against Gram-positive bacteria, including Strep agalactiae, penicillin-resistant Staph aureus and non-penicillinase-producing Staph aureus.
Since 95 percent of infections at dry-off are caused by Gram-positive pathogens,2 DRY-CLOX is a very effective choice.
Each 10-mL, disposable, ready-to-use syringe contains the active ingredient cloxacillin benzathine. At dry-off, at least 30 days prior to calving, after each quarter has been completely milked out, infuse one 10-mL syringe per quarter (500 mg cloxacillin activity per syringe).
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Features & Benefits
Proven Efficacy
In a head-to-head trial, Dry-Clox® (cloxacillin benzathine) treatment worked as well as Spectramast® DC (ceftiofur hydrochloride). There was no statistical difference in the following areas2:
-
Intramammary infections post calving
-
Risk for cure
-
Risk for new infection during the dry period
-
Risk for culling
-
Risk for clinical mastitis before 100 days in milk
-
Dairy Herd Improvement Association (DHIA) test performance for milk, butterfat percent, protein percent and somatic cell count (SCC) up to 100 days in milk (DIM)
Profit Building
-
With zero milk withhold,* DRY-CLOX treatment gets cows back in the milking string soon after calving, giving you more milk to sell and more peace of mind.
-
DRY-CLOX treatment lets you cure dry cow mastitis for less, saving producers, on average, more than 38 percent per cow compared to SPECTRAMAST DC.3
Partial insertion reduces new infections
-
With the Opti-Sert® applicator tip, partial insertion reduces the incidence of new infections during the dry period.
-
Studies have shown that when infusing into the udder at a depth of 2 to 3 millimeters, as opposed to 5 or more millimeters, new intramammary infections can be reduced by as much as 50 percent.1
Part of an effective dry cow protocol
-
DRY-CLOX treatment is part of an effective dry cow protocol that can be used in conjunction with other Boehringer Ingelheim products.
-
Lockout® (bismuth subnitrate) is a better-engineered teat sealant that aids in the prevention of new intramammary infections, and has zero milk withhold.
-
J-Vac® is a broad-spectrum bacterin-toxoid that aids in the prevention of mastitis caused by Escherichia coli and the effects of endotoxemia caused by E. coli and Salmonella Typhimurium.
*DRY-CLOX RESIDUE WARNING: For use in dry cows only. Do not use within 30 days of calving. Any animal infused with this product must not be slaughtered for food until 30 days after the latest infusion.
Dosage & Administration
Presentations
-
Convenient packaging in pails of 144 syringes or cartons of 12 syringes.
-
Each syringe is 10 mL.
Additional Administration Information
Resources
Product Inserts & Labels
Other Resources
Safety
Safety Information
For use in dry cows only. Do not use within 30 days of calving. Any animal infused with this product must not be slaughtered for food until 30 days after the latest infusion.
Because it is a derivative of 6-aminopenicillanic acid, DRY-CLOX has the potential for producing allergic reactions. Such reactions are rare; however, should they occur, the subject should be treated with antihistamines or pressor amines, such as epinephrine.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
OPTI-MIZE with Opti-Sert®
- With the OPTI-SERT tip, partial insertion reduces the incidence of new infections during the dry period.
- Studies have shown that when infusing into the udder at a depth of 2 to 3 millimeters, as opposed to 5 or more millimeters, new intramammary infections can be reduced by as much as 50 percent.1
1. Boddie RL, Nickerson SC and Sutherland SF. New design of mastitis tubes reduces infections. Hoard's Dairyman 1989;134(13):579.
2. Johnson AP, Godden SM, Royster E, et al. Randomized non-inferiority study evaluating the efficacy of two commercial dry cow mastitis formulations. J Dairy Sci 2016;99(1):593–607.
3. Source: Manufacturer pricing to veterinary clinics. Published Dec. 2020 for Zoetis products.
DRY-CLOX® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. All other trademarks are the property of their respective owners. ©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0388-2021